Jiangsu Tianji

Jiangsu Tianji Biopharmaceutical is a specialized biotechnology company based in Taizhou, China, primarily operating as the manufacturing and CMC (Chemistry, Manufacturing, and Controls) arm for I-Mab Biopharma's portfolio. The company focuses on the development and large-scale production of innovative biologics, including recombinant proteins and monoclonal antibodies. Its flagship project is TJ101 (eftansomatropin alfa), a long-acting human growth hormone developed using the HyLeap platform, which is currently in Phase 3 clinical trials. Jiangsu Tianji maintains state-of-the-art GMP facilities designed to support late-stage clinical development and commercial-scale manufacturing. Following a corporate restructuring in 2024, the company continues to serve as a critical infrastructure asset for the China-based operations of the I-Mab group.